Amgen’s Otezla shows promise in psoriatic arthritis
The inflammatory form of arthritis is estimated to affect nearly 38 million people worldwide
Read More
Tag: psoriatic arthritis
NICE recommends Janssen’s treatment for active psoriatic arthritis
Clinical trial evidence suggests that Tremfya is effective when compared with a placebo
Read More
NICE green lights Tremfya to treat active psoriatic arthritis
Tremfya has already been recommended for NHS use to treat eligible patient with moderate-to-severe plaque psoriasis
Read More
Cosentyx gains EU approval for new label extension
Label update includes data for axial manifestations of psoriatic arthritis
Read More
AbbVie’s Rinvoq bags two new EU approvals
Oral JAK inhibitor approved for psoriatic arthritis and ankylosing spondylitis
Read More
Skyrizi bags positive psoriatic arthritis results
KEEPsAKE-1 and KEEPsAKE-2 studies demonstrated significant improvements in Skyrizi-treated patients
Read More
Janssen’s Tremfya approved for active psoriatic arthritis
Tremfya is a first-in-class treatment for the disease, shown to improve disease measures and quality of life
Read More
Novartis’ Cosentyx reduces synovitis in new psoriatic arthritis study
Synovitis (joint lining inflammation) can lead to joint damage in psoriatic arthritis patients
Read More
AbbVie files Rinvoq for psoriatic arthritis
Rinvoq is a selective and reversible JAK inhibitor being studied in several immune-mediated inflammatory diseases
Read More
UK & Irish experts urge for different approach to Psoriatic Arthritis management
The new educational campaign is called ‘Six Domains: One Disease‘.
Read More
Four new therapies to be funded by NHS Scotland
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia, Still’s disease, adrenal insufficiency and psoriatic arthritis.
Read More
EU green light for new Humira biosimilar
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
